The state of Colorado currently has 5 active clinical trials seeking participants for Diabetic Macular Edema research studies. These trials are conducted in various cities, including Denver, Aurora, Colorado Springs and Englewood.
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Colorado Springs, CO, Colorado Springs, Colorado
Conditions: Diabetic Macular Edema (DME)
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Recruiting
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Southwest Retina Consultants, Durango, Colorado
Conditions: Diabetic Macular Edema
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Retina Consultants of Southern CO, Colorado Springs, Colorado
Conditions: Diabetic Macular Edema (DME)
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Recruiting
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications. The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Retina Consultants of Southern Colorado, Colorado Springs, Colorado
Conditions: Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
4D-150 in Patients With Diabetic Macular Edema
Recruiting
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Retina Consultants of Southern Colorado, Colorado Springs, Colorado
Conditions: Diabetic Macular Edema, Diabetic Retinopathy